Compare AbCellera Biologics Inc (ABCL) vs Logitech International SA (LOGI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Logitech International SA — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Logitech International SA trades at $96.95 (market cap $13.85B). The key difference: Logitech International SA is far larger — about 5.9× AbCellera Biologics Inc's market cap, and Logitech International SA pays a 1.75% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | LOGI | |
|---|---|---|
Market Cap | $2.35B | $13.85B |
Sector | Health | Technology |
52-Week High | $8.12 | $126.69 |
52-Week Low | $2.78 | $85.84 |
Enterprise Value | $1.99B | $12.20B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Logitech (LOGI) trades at $97.11, up 3.31% with strong profitability metrics including 43.2% gross margin and 32.78% ROE. The stock shows bearish technical signals despite recent earnings beats, with Q1 2026 EPS of $1.13 exceeding expectations. Recent developments include new gaming partnerships and product launches like the G3 Series and Mobi Fold mouse. Cash flow trends show operational strength with $843M generated in 2025, though net cash flow was slightly negative at -$18M.
Logitech presents a mixed outlook with robust fundamentals offset by technical weakness. The 26% upside to consensus price target of $121.33 offers potential, but bearish moving averages and competitive pressures in peripherals market pose risks. Enterprise momentum and AI-enabled products provide growth catalysts, though investor sentiment remains divided with equal buy/sell analyst ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
